Your account is not claimed yet. You can sign up with ORCID to claim your account.

Katharina Elisabeth Grafinger

ORCID

Publication Activity (10 Years)

Years Active: 2017-2022
Publications (10 Years): 12

Top Venues

Drug testing and analysis

British journal of clinical pharmacology

RSC medicinal chemistry

Inselspital Universitätsspital Bern

Universität Bern (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Inselspital Universitätsspital Bern Jan 1o 2019 - Sep 30o 2019

Switzerland

PostDoc :: Clinical Pharmacology and Toxicology

Education History

Universität Bern - Feb 22o 2019

Switzerland

PHD :: Graduate School of Cell and Biomedical Sciences

Publications

Lorina Otte, Maurice Wilde, Volker Auwärter, Katharina Elisabeth Grafinger
Investigation of the μ- and κ-opioid receptor activation by eight new synthetic opioids using the [ 35 S]-GTPγS assay: U-47700, isopropyl U-47700, U-49900, U-47931E, N-methyl U-47931E, U-51754, U-48520, and U-48800. Drug testing and analysis 14 (7) (2022)
Benedikt Pulver, Jan Riedel, Torsten Schönberger, Sebastian Halter, Tobias Lucas, Till Opatz, Katharina Elisabeth Grafinger, Martin Scheu, Annette Zschiesche, Michael Pütz, Klaus Pützer, Folker Westphal, Volker Auwärter
Pharmacology, prevalence in Germany, and analytical data of cyclobutylmethyl- and norbornylmethyl-type synthetic cannabinoid receptor agonists. Drug testing and analysis (2022)
Katharina Elisabeth Grafinger, Marthe M Vandeputte, Annelies Cannaert, Adam Ametovski, Eric Sparkes, Elizabeth Cairns, Patrick Osamu Juchli, Belal Haschimi, Benedikt Pulver, Samuel D Banister, Christophe P Stove, Volker Auwärter
Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB1 receptor activation assays. Part III: The G protein pathway and critical comparison of different assays. Drug testing and analysis 13 (7) (2021)
Belal Haschimi, Katharina Elisabeth Grafinger, Benedikt Pulver, Evangelia Psychou, Sebastian Halter, Laura M Huppertz, Folker Westphal, Michael Pütz, Volker Auwärter
New synthetic cannabinoids carrying a cyclobutyl methyl side chain: Human Phase I metabolism and data on human cannabinoid receptor 1 binding and activation of Cumyl-CBMICA and Cumyl-CBMINACA. Drug testing and analysis 13 (8) (2021)
Katharina Elisabeth Grafinger, Annelies Cannaert, Adam Ametovski, Eric Sparkes, Elizabeth Cairns, Samuel D Banister, Volker Auwärter, Christophe P Stove
Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB1 receptor activation assays-Part II: Structure activity relationship assessment via a β-arrestin recruitment assay. Drug testing and analysis 13 (7) (2021)
Eric Sparkes, Elizabeth A Cairns, Richard C Kevin, Felcia Lai, Katharina Elisabeth Grafinger, Shuli Chen, Marie H Deventer, Ross Ellison, Rochelle Boyd, Lewis J Martin, Iain S McGregor, Roy R Gerona, David E Hibbs, Volker Auwärter, Michelle Glass, Christophe P Stove, Samuel D Banister
Structure-activity relationships of valine, tert -leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA. RSC medicinal chemistry 13 (2) (2021)
Edward Pike, Katharina Elisabeth Grafinger, Annelies Cannaert, Adam Ametovski, Jia Lin Luo, Eric Sparkes, Elizabeth A Cairns, Ross Ellison, Roy Gerona, Christophe P Stove, Volker Auwärter, Samuel D Banister
Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB1 receptor activation assays: Part I-Synthesis, analytical characterization, and binding affinity for human CB1 receptors. Drug testing and analysis 13 (7) (2021)
Irene Scholz, Evangelia Liakoni, Felix Hammann, Katharina Elisabeth Grafinger, Urs Duthaler, Michael Nagler, Stephan Krähenbühl, Manuel Haschke
Effects of Hypericum perforatum (St John's wort) on the pharmacokinetics and pharmacodynamics of rivaroxaban in humans. British journal of clinical pharmacology 87 (3) (2020)
Katharina Elisabeth Grafinger, Matthias E Liechti, Evangelia Liakoni
Clinical value of analytical testing in patients presenting with new psychoactive substances intoxication. British journal of clinical pharmacology 86 (3) (2019)
Katharina Elisabeth Grafinger, Katja Stahl, Andreas Wilke, Stefan König, Wolfgang Weinmann
In vitro phase I metabolism of three phenethylamines 25D-NBOMe, 25E-NBOMe and 25N-NBOMe using microsomal and microbial models. Drug testing and analysis 10 (10) (2018)
Katharina Elisabeth Grafinger, Andreas Wilke, Stefan König, Wolfgang Weinmann
Investigating the ability of the microbial model Cunninghamella elegans for the metabolism of synthetic tryptamines. Drug testing and analysis 11 (5) (2018)
Katharina Elisabeth Grafinger, Marianne Hädener, Stefan König, Wolfgang Weinmann
Study of the in vitro and in vivo metabolism of the tryptamine 5-MeO-MiPT using human liver microsomes and real case samples. Drug testing and analysis 10 (3) (2017)

Katharina Elisabeth Grafinger.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Katharina Elisabeth Grafinger